Monocyte chemoattractant protein-1 (MCP-1) has been recognized as an angiogenic chemokine. In the present study, we investigated the detailed mechanism by which MCP-1 induces angiogenesis. 
Introduction
Monocyte chemoattractant protein-1 (MCP-1) is a member of the CC chemokine family that plays a crucial role in the initiation and progression of inflammation. 1 MCP-1 binds to its specific CC chemokine receptor 2, CCR2, inducing numerous monocytemediated proinflammatory signals and monocyte chemotaxis. 2, 3 CCR2 is also expressed in vascular endothelial cells in the arterial wall, and MCP-1-induced activation of CCR2 on these cells is known to be responsible for the regeneration of the endothelial layer after injury 4 and angiogenesis and collateral formation 5, 6 in vivo. These processes may be important in the growth of tumors and inflammatory lesions such as atheromatous plaques; however, the detailed mechanism by which MCP-1 induces angiogenesis is still unclear. The present study demonstrates novel evidences that in vivo MCP-1-induced angiogenesis is mediated through pathways involving vascular endothelial growth factor (VEGF) and the activation of RhoA small G protein (RhoA).
Study design

Rat aortic ring assay
Thoracic and abdominal aortas were excised immediately after humane killing from 5-week-old male Sprague-Dawley rats (Samtako, Osan, South Korea). The aorta was transversely cut by 1-mm thickness and embedded in growth factor-deficient Matrigel (Becton Dickinson, Bedford, MA). 5 MCP-1 (10 or 100 ng/mL) was added to the culture media, and microvessel outgrowth was photographed under an IX71 microscope (Olympus, Tokyo, Japan) 48 hours later. The protocol was approved by the Animal Subjects Committee of Asan Medical Center (Seoul, South Korea).
Analysis of HIF-1␣ protein expression
Cell lysate of cultured human aortic endothelial cells (HAECs; American Type Culture Collection, Manassas, VA) was prepared, and the amount of hypoxia-inducible factor 1␣ (HIF-1␣) protein was estimated by immunoblotting assay as described 7 using mouse monoclonal immunoglobulin G (IgG) detecting HIF-1␣ (Novus Biologicals, Littleton, CO). The binding of HIF-1␣ to hypoxia response element (HRE) was analyzed by electrophoretic mobility shift assay (EMSA) as described 8 using [␥-32 P]adenosine triphosphate ([␥-32 P]ATP)-end-labeled oligonucleotides containing sequences of HRE 5Ј-TCTGTACGTGACCACACTCACCTC-3Ј (Santa Cruz Biotechnology, Santa Cruz, CA).
Analysis of VEGF-A 165 mRNA expression
Expression of VEGF-A 165 mRNA by excised rat aorta was estimated by real-time polymerase chain reaction (PCR) with SYBR Green I 7 using the specific primers 5Ј-CCCTGGCTTTACTGCTGTAC-3Ј (sense) and 5Ј-TCTGAACAAGGCTCA-CAGTG-3Ј (antisense). As an internal standard, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was amplified and analyzed under identical conditions using the specific primers 5Ј-TCGGACTCAACGGATTTG-GTCGTA-3Ј (sense) and 5Ј-ATGGACTGTGGTCAGAGTCCTTC-3Ј (antisense). The Ct value (the cycle number at which emitted fluorescence exceeded an automatically determined threshold) for VEGF-A 165 was corrected by the Ct value for GAPDH and expressed as ⌬Ct. Data were expressed as fold changes of the VEGF mRNA amount, which was calculated as follows: fold changes ϭ 2 (⌬Ct for control cells Ϫ ⌬Ct for MCP-1-treated cells) .
Measurement of VEGF-A 165 concentration
A total of 4 ϫ 10 5 HAECs (6 to 8 passages) were cultured on a 24-well plate in endothelial growth medium-2 (EGM-2) complete medium (Clonetics, Walkersville, MD) containing 10% fetal bovine serum (FBS) until 70% to 90% confluency and treated for 24 hours with MCP-1 (10 or 100 ng/mL), and the concentration of VEGF-A 165 in the culture media was measured using a commercial enzyme-linked immunosorbent assay ELISA kit (R&D Systems, Minneapolis, MN), which detected a minimum VEGF-A concentration of 1.76 pg/mL with a 4% to 6% coefficient of variance.
Chorioallantoic membrane assay
To estimate MCP-1-induced in vivo angiogenesis, 5 a mixture of 10 L MCP-1 (10 ng/mL) and 10 L type I collagen (Collaborative Biomedical Products, Bedford, MA) was applied to a quartered Nunc Thermanox plastic coverslip with 13-mm diameter (Nalge Nunc International, Naperville, IL) and allowed to dry for 30 minutes. The coverslip was immediately placed onto chick chorioallantoic membrane (CAM) of 10-day-old fertilized eggs. After 3 days, the CAM surface was photographed with a Nikon Coolpix 4300 camera (Nikon, Tokyo, Japan), and the number of newly formed vessels radiating from the sample spot was counted. Phosphatebuffered saline (PBS) containing 0.1% bovine serum albumin (BSA) or human recombinant VEGF-A 165 (10 g/mL) was used as negative and positive controls, respectively.
Statistical analysis
All data are represented as mean Ϯ SE. Mann-Whitney U tests were performed to assess significance of changes compared with controls.
Asterisks in the figures represent P values of less than .05 in terms of statistical significance.
Results and discussion
Our ex vivo rat aortic ring assay showed that 10 ng/mL MCP-1 significantly increased the sprouting of capillaries, whereas a higher MCP-1 concentration (100 ng/mL) was not as effective ( Figure 1A ). This MCP-1-stimulated capillary formation was completely inhibited by the Rho inhibitor, Clostridium difficile toxin, and by the RhoA inhibitor, C3 transferase. We confirmed CCR2 expression in HAECs and rat arterial wall, as determined by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Our preliminary in vitro assays showed that the stimulation of cultured HAEC monolayers with MCP-1 increased HAEC proliferation by 20%, as estimated by the amount of 3 H-thymidine incorporated (data not shown). Taken together, our findings strongly suggest that angiogenesis induced by MCP-1 is solely due to the activation of the arterial wall and does not require inflammatory leukocytes. 5 The present study demonstrates novel evidences that MCP-1 induces gene expression of HIF-1␣ by HAECs ( Figure 1B ). As expected, this increase in HIF-1␣ expression induced VEGF gene expression. Our RT-PCR and real-time PCR results clearly showed that MCP-1 induced gene expression of VEGF-A 165 , a main VEGF isoform that induces angiogenesis, by the cultured arterial walls ( Figure 1C ) and HAECs (data not shown), whereas the mRNA expression levels of VEGF-C and VEGF-D isoforms showed To chorioallantoic membranes (CAMs) of 10-day-old chick embryos, MCP-1 (10 ng/mL) and, where indicated, Flt2-11 (1 mg/mL; Calbiochem, San Diego, CA), C difficile toxin (20 ng/mL), C3 transferase (100 g/mL), or 10 M PD98059 (p42/44 MAPK inhibitor) was applied as described in "Study design." Bovine serum albumin (BSA; 20 ng/mL) and VEGF (10 g/mL) were used as negative and positive controls, respectively. (A) After 72 hours of incubation, newly formed blood vessels were photographed. (B) The number of newly formed vessels radiating from the applied spot was counted by 2 independent observers. f indicates VEGF-A165 or MCP-1 alone; Ⅺ, with Flt2-11; u, with C difficile; o, with C3 transferase; and z, with PD98059. Data are shown as means Ϯ SE. *P Ͻ .05, as determined by Mann-Whitney U test.
relatively small changes. A maximal 4-fold increase in VEGF-A 165 mRNA expression after MCP-1 stimulation was accompanied by dramatic increases in VEGF-A 165 production by HAEC monolayers, as determined by ELISA ( Figure 1D ). Taken together with previous studies showing VEGF-induced MCP-1 secretion by vascular endothelial cells, 9,10 a positive regulatory feedback loop between VEGF and MCP-1 expression may escalate inflammatory responses and angiogenesis per se. Our data further show the involvement of p42/44 mitogen-activated protein kinase (MAPK) in MCP-1-stimulated VEGF-A production. As previously described, p42/44 MAPK mediates nonhypoxic signals to induce HIF-1␣ gene expression and enhance HIF-1␣ stabilization 11 and hence initiates VEGF-induced angiogenesis.
Activation of CCR2, a G protein-coupled receptor (GPCR), triggers numerous signalings, 12, 13 including activation of small G proteins. Our in vivo CAM assays consistently reproduced the results with ex vivo rat aortic ring assays showing that MCP-1-mediated angiogenesis was inhibited by Rho and RhoA inhibitors (Figure 2 ), suggesting the pivotal role of Rho in MCP-1-induced angiogenesis. However, our ELISA results showed that RhoA inhibition had little effects on MCP-1-stimulated VEGF-A 165 production by HAECs ( Figure 1C ), indicating CCR2-dervied RhoA activation is not involved in VEGF regulation. On the other hand, our in vivo CAM assays clearly showed that VEGF-A 165 -induced angiogenesis was profoundly blocked by RhoA inhibition, indicating RhoA, which is activated by VEGF-A and not by MCP-1, activates endothelial cells to trigger the process of both MCP-1-and VEGF-A-induced angiogenesis (Figure 2 ). Previous reports support our findings that Rho is activated by vascular endothelial cells upon stimulation with VEGF. Rho mediates the VEGF-induced migration and proliferation of endothelial cells, 14 and induces tyrosine phosphorylation of several signaling proteins after activation of VEGF receptor 2. 15 Several reports suggest that other VEGF-independent mechanisms may possibly be involved in MCP-1-induced angiogenesis, such as MCP-1-mediated migration of vascular endothelial cells 4 and Rho-mediated endothelial organization 16 and cytosolic stress fiber formation in the cytosol of HAECs. 17 Our preliminary experiment also confirmed that MCP-1 Rho-dependently induced transmigration and actin polymerization of HAECs (data not shown). However, we clearly observed that MCP-1-induced angiogenesis was completely blocked by a specific VEGF inhibitor, Flt 2-11 , indicating that VEGF mainly orchestrates MCP-1-induced angiogenesis (Figure 2) .
Taken together, the present study provides compelling evidence that MCP-1-induced angiogenesis is composed largely of 2 sequential steps: the induction of VEGF-A gene expression by MCP-1 and the subsequent VEGF-A-induced angiogenesis. Notably, MCP-1-induced angiogenesis measured as potent as that induced by VEGF-A. Such a potential benefit of MCP-1 on vascular remodeling may provide background for therapeutic use of MCP-1 for arterioocclusive diseases.
